194 related articles for article (PubMed ID: 9154316)
1. Megakaryocytes and platelets in myeloproliferative disorders.
Briere J; Kiladjian JJ; Peynaud-Debayle E
Baillieres Clin Haematol; 1997 Feb; 10(1):65-88. PubMed ID: 9154316
[TBL] [Abstract][Full Text] [Related]
2. [Dysmegakaryocytopoiesis and dysthrombopoiesis in myeloproliferative syndromes].
Brière J; Kiladjian JJ; Peynaud-Debayle E
C R Seances Soc Biol Fil; 1996; 190(5-6):533-9. PubMed ID: 9074718
[TBL] [Abstract][Full Text] [Related]
3. Clonality assays and megakaryocyte culture techniques in essential thrombocythemia.
Yan L; Elkassar N; Gardin C; Briere J
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():31-40. PubMed ID: 8951770
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia.
Michiels JJ
Neth J Med; 1997 Aug; 51(2):57-64. PubMed ID: 9286142
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
Michiels JJ; Thiele J
Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
[TBL] [Abstract][Full Text] [Related]
7. Flow cytometric analysis of megakaryocyte ploidy in chronic myeloproliferative disorders and reactive thrombocytosis.
Jacobsson S; Carneskog J; Ridell B; Wadenvik H; Swolin B; Kutti J
Eur J Haematol; 1996 May; 56(5):287-92. PubMed ID: 8641402
[TBL] [Abstract][Full Text] [Related]
8. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Michiels JJ; Juvonen E
Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
[TBL] [Abstract][Full Text] [Related]
9. [Megakaryocytopoiesis in myeloproliferative disorders].
Podolak-Dawidziak M
Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
[No Abstract] [Full Text] [Related]
10. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
11. Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders.
Li Y; Hetet G; Kiladjian JJ; Gardin C; Grandchamp B; Briere J
Br J Haematol; 1996 Jan; 92(1):60-6. PubMed ID: 8562412
[TBL] [Abstract][Full Text] [Related]
12. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders.
Martyré MC
Leuk Lymphoma; 1995 Dec; 20(1-2):39-44. PubMed ID: 8750621
[TBL] [Abstract][Full Text] [Related]
13. Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis--features of significance for the diagnosis of primary (essential) thrombocythaemia.
Thiele J; Schneider G; Hoeppner B; Wienhold S; Zankovich R; Fischer R
Virchows Arch A Pathol Anat Histopathol; 1988; 413(5):407-17. PubMed ID: 3140482
[TBL] [Abstract][Full Text] [Related]
14. The chronic myeloproliferative disorders: clonality and clinical heterogeneity.
Spivak JL
Semin Hematol; 2004 Apr; 41(2 Suppl 3):1-5. PubMed ID: 15190515
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF.
Li Y; Hetet G; Maurer AM; Chait Y; Dhermy D; Briere J
Br J Haematol; 1994 Jul; 87(3):471-6. PubMed ID: 7993786
[TBL] [Abstract][Full Text] [Related]
16. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous measurement of serum thrombopoietin and expression of megakaryocyte c-Mpl with clinical and laboratory correlates for myelofibrosis with myeloid metaplasia.
Elliot MA; Yoon SY; Kao P; Li CY; Tefferi A
Eur J Haematol; 2002 Mar; 68(3):175-9. PubMed ID: 12068799
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
19. Nucleolar organizer regions of megakaryocytes in chronic myeloproliferative disorders.
Matolcsy A; Nádor R; Wéber E; Kónya T
Virchows Arch A Pathol Anat Histopathol; 1992; 420(5):441-5. PubMed ID: 1375798
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
Michiels JJ
Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
